Neuromuscular blocking drugs in the intensive care unit: Introductory remarks J. F. BionB. J. Pollard BriefCommunication Pages: S35 - S35
The use of neuromuscular blocking drugs in the intensive care unit: A US perspective M. J. MurrayR. A. StricklandC. Weiler OriginalPaper Pages: S40 - S44
Physiology and pharmacology of neuromuscular transmission, with special reference to the possible consequences of prolonged blockade W. C. Bowman OriginalPaper Pages: S45 - S53
The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill R. J. M. RossJ. Rodriguez-ArnaoJ. H. Coakley OriginalPaper Pages: S54 - S57
Monitoring neuromuscular function in the Intensive Care Unit J. Viby-Mogensen OriginalPaper Pages: S74 - S79
Neuromuscular blocking drugs: Practical aspects of research in the intensive care unit N. J. N. Harper OriginalPaper Pages: S80 - S85
Atracurium and laudanosine pharmacokinetics in acute renal failure J. M. Hunter BriefCommunication Pages: S91 - S93
Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation J. F. BionM. I. BowdenB. C. Weatherley OriginalPaper Pages: S94 - S98